Michelle Gilson
Stock Analyst at Morgan Stanley
(1.09)
# 3,784
Out of 4,996 analysts
31
Total ratings
32.14%
Success rate
-7.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $5.49 | +264.30% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $83.87 | -64.23% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $9.34 | +82.01% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $191.99 | +2.09% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $25.30 | +77.87% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $24.14 | +214.83% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $53.85 | +68.99% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $5.49
Upside: +264.30%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $83.87
Upside: -64.23%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $9.34
Upside: +82.01%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $191.99
Upside: +2.09%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $25.30
Upside: +77.87%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $24.14
Upside: +214.83%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $53.85
Upside: +68.99%